Chris Howerton
Stock Analyst at Jefferies
(2.63)
# 1,948
Out of 5,182 analysts
67
Total ratings
43.4%
Success rate
18.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $7.00 | +7.14% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $53.48 | +133.73% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.94 | +34.68% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.38 | +189.86% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.29 | +336.68% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.18 | +29,730.51% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $17.76 | +3,954.05% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $2.26 | -77.88% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $18.82 | -46.87% | 1 | Feb 8, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $40.41 | -1.01% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $27.74 | +119.90% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $168.51 | -46.59% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.03 | +61,819.50% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $31.06 | +112.49% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.00 | +340.00% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.01 | +1,979.21% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.01 | +2,078.22% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $22.20 | -5.38% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $9.27 | +6,156.74% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $2.00 | +2,900.00% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $42.49 | -62.34% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $103.78 | -73.98% | 1 | Jul 15, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $7.00
Upside: +7.14%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $53.48
Upside: +133.73%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.94
Upside: +34.68%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.38
Upside: +189.86%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.29
Upside: +336.68%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.18
Upside: +29,730.51%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $17.76
Upside: +3,954.05%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $2.26
Upside: -77.88%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $18.82
Upside: -46.87%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $40.41
Upside: -1.01%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $27.74
Upside: +119.90%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $168.51
Upside: -46.59%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.03
Upside: +61,819.50%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $31.06
Upside: +112.49%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.00
Upside: +340.00%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.01
Upside: +1,979.21%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.01
Upside: +2,078.22%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $22.20
Upside: -5.38%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $9.27
Upside: +6,156.74%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $2.00
Upside: +2,900.00%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $42.49
Upside: -62.34%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $103.78
Upside: -73.98%